These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 9630231)

  • 1. Partial V(D)J recombination activity leads to Omenn syndrome.
    Villa A; Santagata S; Bozzi F; Giliani S; Frattini A; Imberti L; Gatta LB; Ochs HD; Schwarz K; Notarangelo LD; Vezzoni P; Spanopoulou E
    Cell; 1998 May; 93(5):885-96. PubMed ID: 9630231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omenn syndrome does not live by V(D)J recombination alone.
    Marrella V; Maina V; Villa A
    Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):525-31. PubMed ID: 22001740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations.
    Villa A; Sobacchi C; Notarangelo LD; Bozzi F; Abinun M; Abrahamsen TG; Arkwright PD; Baniyash M; Brooks EG; Conley ME; Cortes P; Duse M; Fasth A; Filipovich AM; Infante AJ; Jones A; Mazzolari E; Muller SM; Pasic S; Rechavi G; Sacco MG; Santagata S; Schroeder ML; Seger R; Strina D; Ugazio A; Väliaho J; Vihinen M; Vogler LB; Ochs H; Vezzoni P; Friedrich W; Schwarz K
    Blood; 2001 Jan; 97(1):81-8. PubMed ID: 11133745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omenn syndrome: a disorder of Rag1 and Rag2 genes.
    Villa A; Santagata S; Bozzi F; Imberti L; Notarangelo LD
    J Clin Immunol; 1999 Mar; 19(2):87-97. PubMed ID: 10226883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The genetic and biochemical basis of Omenn syndrome.
    Santagata S; Villa A; Sobacchi C; Cortes P; Vezzoni P
    Immunol Rev; 2000 Dec; 178():64-74. PubMed ID: 11213808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of immune function and analysis of RAG gene mutations in Omenn syndrome and related disorders.
    Wada T; Takei K; Kudo M; Shimura S; Kasahara Y; Koizumi S; Kawa-Ha K; Ishida Y; Imashuku S; Seki H; Yachie A
    Clin Exp Immunol; 2000 Jan; 119(1):148-55. PubMed ID: 10606976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunophenotypic and immunogenotypic B-cell differentiation arrest in bone marrow of RAG-deficient SCID patients corresponds to residual recombination activities of mutated RAG proteins.
    Noordzij JG; de Bruin-Versteeg S; Verkaik NS; Vossen JM; de Groot R; Bernatowska E; Langerak AW; van Gent DC; van Dongen JJ
    Blood; 2002 Sep; 100(6):2145-52. PubMed ID: 12200379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical, immunologic, and genetic characteristics of RAG mutations in 15 Chinese patients with SCID and Omenn syndrome.
    Bai X; Liu J; Zhang Z; Liu C; Zhang Y; Tang W; Dai R; Wu J; Tang X; Zhang Y; Ding Y; Jiang L; Zhao X
    Immunol Res; 2016 Apr; 64(2):497-507. PubMed ID: 26476733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Omenn Syndrome and DNA recombination defects].
    Yachie A
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(3):179-189. PubMed ID: 28747605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of mutations and recombination activity in RAG-deficient patients.
    Asai E; Wada T; Sakakibara Y; Toga A; Toma T; Shimizu T; Nampoothiri S; Imai K; Nonoyama S; Morio T; Muramatsu H; Kamachi Y; Ohara O; Yachie A
    Clin Immunol; 2011 Feb; 138(2):172-7. PubMed ID: 21131235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Similar recombination-activating gene (RAG) mutations result in similar immunobiological effects but in different clinical phenotypes.
    IJspeert H; Driessen GJ; Moorhouse MJ; Hartwig NG; Wolska-Kusnierz B; Kalwak K; Pituch-Noworolska A; Kondratenko I; van Montfrans JM; Mejstrikova E; Lankester AC; Langerak AW; van Gent DC; Stubbs AP; van Dongen JJ; van der Burg M
    J Allergy Clin Immunol; 2014 Apr; 133(4):1124-33. PubMed ID: 24418478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omenn's syndrome occurring in patients without mutations in recombination activating genes.
    Gennery AR; Hodges E; Williams AP; Harris S; Villa A; Angus B; Cant AJ; Smith JL
    Clin Immunol; 2005 Sep; 116(3):246-56. PubMed ID: 15964782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oligoclonal expansion of T lymphocytes with multiple second-site mutations leads to Omenn syndrome in a patient with RAG1-deficient severe combined immunodeficiency.
    Wada T; Toma T; Okamoto H; Kasahara Y; Koizumi S; Agematsu K; Kimura H; Shimada A; Hayashi Y; Kato M; Yachie A
    Blood; 2005 Sep; 106(6):2099-101. PubMed ID: 15845893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics and molecular analysis of three Chinese children with Omenn syndrome.
    Zhang ZY; Zhao XD; Jiang LP; Liu EM; Cui YX; Wang M; Wei H; Yu J; An YF; Yang XQ
    Pediatr Allergy Immunol; 2011 Aug; 22(5):482-7. PubMed ID: 21771083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identical mutations in RAG1 or RAG2 genes leading to defective V(D)J recombinase activity can cause either T-B-severe combined immune deficiency or Omenn syndrome.
    Corneo B; Moshous D; Güngör T; Wulffraat N; Philippet P; Le Deist FL; Fischer A; de Villartay JP
    Blood; 2001 May; 97(9):2772-6. PubMed ID: 11313270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in understanding RAG deficiencies.
    Gennery A
    F1000Res; 2019; 8():. PubMed ID: 30800289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human syndromes of immunodeficiency and dysregulation are characterized by distinct defects in T-cell receptor repertoire development.
    Yu X; Almeida JR; Darko S; van der Burg M; DeRavin SS; Malech H; Gennery A; Chinn I; Markert ML; Douek DC; Milner JD
    J Allergy Clin Immunol; 2014 Apr; 133(4):1109-15. PubMed ID: 24406074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. V(D)J recombination catalyzed by mutant RAG proteins lacking consensus DNA-PK phosphorylation sites.
    Lin JM; Landree MA; Roth DB
    Mol Immunol; 1999 Dec; 36(18):1263-9. PubMed ID: 10684966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omenn syndrome in the context of other B cell-negative severe combined immunodeficiencies.
    Villa A; Sobacchi C; Vezzoni P
    Isr Med Assoc J; 2002 Mar; 4(3):218-21. PubMed ID: 11908269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omenn syndrome due to ARTEMIS mutations.
    Ege M; Ma Y; Manfras B; Kalwak K; Lu H; Lieber MR; Schwarz K; Pannicke U
    Blood; 2005 Jun; 105(11):4179-86. PubMed ID: 15731174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.